<DOC>
	<DOCNO>NCT01535547</DOCNO>
	<brief_summary>The purpose study assess effect multiple dose isavuconazole pharmacokinetics ( PK ) tacrolimus single dose administration .</brief_summary>
	<brief_title>Drug Interaction Study Isavuconazole Tacrolimus</brief_title>
	<detailed_description>Subjects receive single dose tacrolimus Day 1 follow 15 day wash-out period ( time tacrolimus dose isavuconazole dosing ) . On Days 16 17 , isavuconazole dose three time daily ( TID ) . TID dose administer 8 hour apart . On Days 18 28 isavuconazole administer daily ( QD ) . All subject administer single dose tacrolimus Day 20 . A follow visit occur approximately 7 day last dose isavuconazole . Blood sample pharmacokinetics collect throughout study .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>The subject must weigh least 45 kg body mass index ( BMI ) 18 32 kg/m2 , inclusive The subject normal 12lead electrocardiogram ( ECG ) The subject 's clinical laboratory test result within normal limit Results aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin must within normal range If female , subject agree sexual abstinence , surgically sterile , postmenopausal ( define least 2 year without menses ) , use medically acceptable double barrier method prevent pregnancy agree continue use method Screening three week follow visit end study ; lactate pregnant document negative serum pregnancy test If male , subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy study period three week follow visit end study Any clinically significant disease history follow system : pulmonary , gastrointestinal , cardiovascular ( include history clinically significant arrhythmia clinically significant conduction delay ECG ) , hepatic , neurological , psychiatric , renal , genitourinary , endocrine , metabolic , dermatologic , immunologic , hematologic , malignancy exclude non melanoma skin cancer The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history Long QT syndrome ( suggest sudden death close relative young age due possible probable cardiac cause ) History tuberculosis exposure anyone know suspected tuberculosis illness might confound result study pose additional risk administer study drug subject The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic admission The subject receive vaccination within last 30 day prior study drug administration plan receive vaccination within 2 week last dose study drug The subject positive result hepatitis B surface antigen , hepatitis C antibody , QuantiFERONÂ®TB Gold test ( ) know positive human immunodeficiency virus The subject know suspect allergy component trial product include tacrolimus azole class compound history multiple and/or severe allergy drug food history hypersensitivity polyoxyl 60 hydrogenated castor oil , history severe anaphylactic reaction The subject smoker ( use tobacco nicotine containing product ) last 6 month The subject treatment prescription drug complementary alternative medicine within 14 day prior study drug administration , overthecounter medication within 1 week prior Day 1 , exception acetaminophen 2 g/day The subject receive experimental agent within 30 day 5 halflives , whichever longer , prior Day 1 The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission The subject take part strenuous exercise within 3 day dose trial The subject anticipate inability abstain caffeine alcohol use 48 hour prior clinic admission throughout duration study ; grapefruit , grapefruit juice , star fruit , Seville oranges product contain item 72 hour prior clinic admission throughout duration study The subject recent history ( within last 2 year ) drug alcohol abuse , positive drug screen The subject condition precludes subject 's participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>isavuconazole</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>BAL8557</keyword>
</DOC>